---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-112973"
form_type: "8-K"
ticker: "DFTX"
cik: "0001813814"
company_name: "Definium Therapeutics, Inc."
filed_at: "2025-09-04T23:59:59+00:00"
generated_at: "2026-05-17T08:20:48.303735+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# MindMed publishes Phase 2b results for MM120 (LSD) in GAD in JAMA; 100 µg dose meets endpoints

## Summary
- MM120 100 µg showed 7.6-point greater HAM-A reduction vs placebo at Week 4 (p<0.0004, d=0.88); 65% response rate, 48% remission at Week 12.
- Phase 2b study in 198 adults with moderate-to-severe GAD met primary and key secondary endpoints; dose-response demonstrated.
- MM120 was well-tolerated; adverse events mild-to-moderate, transient, consistent with LSD effects.
- FDA granted Breakthrough Therapy Designation for MM120 in GAD; Phase 3 trials (Voyage, Panorama, Emerge) enrolling.

## SEC filing metadata
- accession: 0000950170-25-112973
- form_type: 8-K
- ticker: DFTX
- cik: 0001813814
- company_name: Definium Therapeutics, Inc.
- filed_at: 2025-09-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1813814/000095017025112973/0000950170-25-112973-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1813814/000095017025112973/mnmd-20250904.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-112973
- JSON: https://secwatch.observer/filing/0000950170-25-112973.json
- Plain text: https://secwatch.observer/filing/0000950170-25-112973.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.